Recent developments indicate that China is positioning itself as a formidable competitor in the field of drug innovation.
The introduction of strict supply chain regulations could complicate operations for Western biopharma firms, raising concerns about their ability to adapt.
As China aims to maintain its competitive edge, the implications of these regulations warrant close attention from industry stakeholders.